Navigation Links
Organovo To Present At Lazard Healthcare Conference
Date:11/7/2012

SAN DIEGO, Nov. 7, 2012 /PRNewswire/ -- Organovo Holdings, Inc. (OTCQB: ONVO) ("Organovo"), a developer and manufacturer of functional human tissues using a novel three-dimensional  bioprinting technology, today announced that Keith Murphy, Chairman and Chief Executive Officer, will present at the upcoming Lazard Capital Markets 9th Annual Healthcare Conference in New York.  Mr. Murphy is expected to present on Wednesday, November 14, 2012. 

About Organovo Holdings, Inc.

Organovo designs and creates functional human tissues using a proprietary three dimensional bioprinting technology. The Company focuses on developing a range of human tissues and disease models for medical research and therapeutic applications.  The Company's NovoGen three-dimensional bioprinting technology uses a specialized automated platform that works across all tissue and cell types. Organovo's NovoGen MMX Bioprinter was selected as one of the "Best Inventions of 2010" by TIME Magazine. Organovo is helping pharmaceutical partners develop human biological disease models in three dimensions that enable therapeutic drug discovery and development. Organovo's technology can also be applied to create surgical tissues for direct therapy. Organovo leads the way in solving complex medical research problems and building the future of medicine. For more information, please visit http://www.organovo.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and
'/>"/>

SOURCE Organovo Holdings, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
2. Organovo, Inc. to Webcast, Live, at RetailInvestorConferences.com on March 1st
3. Organovo, Inc. Investor Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com
4. Organovo Announces Close of $15.2 Million Private Placement to Advance 3D Bioprinting for Medical Applications
5. Organovo Announces Relocation and Commencement of Operations at Larger Facility
6. Organovo Holdings, Inc. to Webcast, Live, at RetailInvestorConferences.com on August 2nd
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
10. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
11. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... KS (PRWEB) August 19, 2014 ... offer fast and cost-effective metabolite production from bioactive ... proprietary chemistry platform, the technology enables convenient and ... According to XenoTech’s Vice President of Commercial ... synthesis for assessing clinical risk can be measured ...
(Date:8/19/2014)... VANCOUVER , Aug. 19, 2014 /PRNewswire/ - iCo ... (OTCQX: ICOTF), today reported results of its Oral ... latent HIV reservoirs.  The study, conducted by ImmuneCarta®, ... in vitro effectiveness of Oral Amp ... remain present in individuals despite intensive treatment with ...
(Date:8/18/2014)... 18, 2014 BioElectronics Corporation (OTC ... medical devices said that its EVP Dr. ... CEOLIVE.TV as part of its Executive Interview ... available at http://ceolive.tv/bioelectronics-corp-otc-biel/biel-videos/2282-ceolive-tv-interview-bioelectronics-corp-otcqb-biel ... investors the unique advantages of BioElectronics patented ...
(Date:8/18/2014)... August 18, 2014 According ... Market, By Application (Municipal Wastewater Treatment and Industrial ... and Multi Tubular), By Configuration (Internal/Submerged and External/Sidestream), ... by MarketsandMarkets, The market for membrane bioreactor systems ... growing at a CAGR of 15.28% between 2014 ...
Breaking Biology Technology:Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3
... 2011 The 10th annual Evergreen Healthcare Foundation Gala ... and friends of the hospital together at King County,s ... million to kick off a capital campaign that will ... imaging technology.   The "Evening in Paris" ...
... At this year,s American Academy of AntiAging (A4M) conference, ... leading factors in premature aging and disease. AGEs are dangerous ... sugar that attaches to a protein or lipid without the ... completely irreversible—and cause accelerated damage to the tissues and cells. ...
... /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA ), ... it will release its unaudited financial results for the first ... 13, 2011.  The Company will host a conference call on ... 2011 at 8:00 pm China Standard Time) to review the ...
Cached Biology Technology:Evergreen Foundation Gala Raises $1.16 Million for Cancer Care, Kicks off Capital Campaign 2At This Year's American Academy of AntiAging (A4M) Conference, Glycation and AGEs (Advanced Glycation End Products) Were Named the Leading Factors in Premature Aging and Disease 2Sinovac to Host Conference Call to Report First Quarter 2011 Unaudited Financial Results 2
(Date:8/19/2014)... many parts of the world, leprosy and tuberculosis ... cases of leprosy per year, with nearly all ... currently available century-old vaccine Bacille Calmette-Guerin, or BCG, ... leprosy, so a more potent vaccine is needed ... found a stronger weapon against both diseases., In ...
(Date:8/19/2014)... with neonatal abstinence syndrome (NAS) secondary to in-utero ... through withdrawal than others, but the underlying reasons ... (when genes are turned on or off) changes ... at Boston University School of Medicine (BUSM) and ... its kind study to identify some of these ...
(Date:8/19/2014)... Science Center at San Antonio and The University of ... of more than $750,000 in grants through the San ... in 2003, SALSI is a model of how a ... center join forces for greater research and graduate education. ... focus on public health issues and diseases of global ...
Breaking Biology News(10 mins):New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2San Antonio Life Sciences Institute awards $750,000 to innovators 2San Antonio Life Sciences Institute awards $750,000 to innovators 3
... Two chemicals -- trichloroethylene (TCE) and tetrachloroethylene (PCE) -- ... Base Camp Lejeune from the 1950s to 1985 have ... cancers. A new report from the National Research ... Potential Health Effects, reviews scientific evidence about the potential ...
... humans have evolved to naturally understand things like facial expressions ... found there is an ever-widening gap between what humans can ... successful adults in today,s modern society. Schools have traditionally helped ... the U.S. more may need to be done. "Schools ...
... Australian company Stadvis Pty Ltd have signed a worldwide ... predicts glycemic index (GI) and resistant starch (RS) in ... with an accurate means of testing the functional properties ... is much quicker and more cost-effective than the current ...
Cached Biology News:MU study finds connection between evolution, classroom learning 2CSIRO deal to commercialize 'artificial gut' 2
Immunochemistry 1 & 2...
... A.P. Johnstone and M.W. Turner ... strategies and methods used in the ... of antibodies in immunoassays, the standardisation ... ELISA techniques including amplification systems, enzyme ...
Supplemental reagent for annexin V assay....
See product name for description....
Biology Products: